DE2127159C2 - IgG-Immunglobulinfraktion und ihre Herstellung - Google Patents
IgG-Immunglobulinfraktion und ihre HerstellungInfo
- Publication number
- DE2127159C2 DE2127159C2 DE19712127159 DE2127159A DE2127159C2 DE 2127159 C2 DE2127159 C2 DE 2127159C2 DE 19712127159 DE19712127159 DE 19712127159 DE 2127159 A DE2127159 A DE 2127159A DE 2127159 C2 DE2127159 C2 DE 2127159C2
- Authority
- DE
- Germany
- Prior art keywords
- solution
- igg
- blood
- plasma
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims description 17
- 102000018358 immunoglobulin Human genes 0.000 title claims description 17
- 238000004519 manufacturing process Methods 0.000 title description 4
- 210000002381 plasma Anatomy 0.000 claims description 18
- 102000006395 Globulins Human genes 0.000 claims description 17
- 108010044091 Globulins Proteins 0.000 claims description 17
- 239000002202 Polyethylene glycol Substances 0.000 claims description 17
- 229920001223 polyethylene glycol Polymers 0.000 claims description 17
- 238000001556 precipitation Methods 0.000 claims description 17
- 238000005119 centrifugation Methods 0.000 claims description 11
- 210000000601 blood cell Anatomy 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- 238000000034 method Methods 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 230000008569 process Effects 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000005194 fractionation Methods 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 102000004506 Blood Proteins Human genes 0.000 description 7
- 108010017384 Blood Proteins Proteins 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 6
- 150000001768 cations Chemical class 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000008946 Fibrinogen Human genes 0.000 description 5
- 108010049003 Fibrinogen Proteins 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 229940012952 fibrinogen Drugs 0.000 description 5
- 239000007974 sodium acetate buffer Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000012064 sodium phosphate buffer Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229920002491 Diethylaminoethyl-dextran Polymers 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE763270A SE348942B (cg-RX-API-DMAC7.html) | 1970-06-02 | 1970-06-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2127159A1 DE2127159A1 (de) | 1971-12-09 |
| DE2127159C2 true DE2127159C2 (de) | 1981-12-24 |
Family
ID=20271889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712127159 Expired DE2127159C2 (de) | 1970-06-02 | 1971-06-01 | IgG-Immunglobulinfraktion und ihre Herstellung |
Country Status (8)
| Country | Link |
|---|---|
| AT (1) | AT309678B (cg-RX-API-DMAC7.html) |
| CA (1) | CA960964A (cg-RX-API-DMAC7.html) |
| CH (1) | CH572745A5 (cg-RX-API-DMAC7.html) |
| DE (1) | DE2127159C2 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2100716B1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB1344340A (cg-RX-API-DMAC7.html) |
| NL (1) | NL177599C (cg-RX-API-DMAC7.html) |
| SE (1) | SE348942B (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2751717A1 (de) * | 1976-12-03 | 1978-07-13 | Myer Louis Dr Coval | Neue verbesserte gammaglobuline fuer intravenoese injektion und verfahren zu ihrer herstellung |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE389596B (sv) * | 1974-06-14 | 1976-11-15 | P G S Lindroos | Saett att ur en vaetska innehallande blodsubstanser separera jaernfoereningar fran globin |
| DE2500076C3 (de) * | 1975-01-02 | 1982-11-18 | SCHURA Blutderivate GmbH & Co KG, 4150 Krefeld | Verfahren zur Gewinnung von intravenös-verträglichen Gammaglobulinen |
| AT359641B (de) * | 1978-09-19 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines intravenoes ver- abreichbaren antikoerperhaeltigen immunglobulin- praeparates |
| US4315851A (en) | 1978-12-29 | 1982-02-16 | Kureha Kagaku Kogyo Kabushiki Kaisha | Pharmaceutical composition having antitumor activity |
| WO2010082894A1 (en) * | 2009-01-13 | 2010-07-22 | Ge Healthcare Bio-Sciences Ab | Precipitation of biomolecules with negatively charged polymers |
| SG176256A1 (en) | 2009-05-27 | 2012-01-30 | Baxter Int | A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use |
| IT1397061B1 (it) * | 2009-12-28 | 2012-12-28 | Kedrion Spa | Nuovo processo di purificazione su scala industriale di gammaglobuline da plasma umano per uso industriale. |
| US8796430B2 (en) | 2010-05-26 | 2014-08-05 | Baxter International Inc. | Method to produce an immunoglobulin preparation with improved yield |
| WO2011150284A2 (en) | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
| AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| EP2748193B1 (en) | 2011-08-26 | 2017-02-01 | Baxalta GmbH | Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition |
| TWI629283B (zh) | 2012-02-23 | 2018-07-11 | 巴克斯歐塔公司 | 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱 |
| US8986670B2 (en) | 2012-02-29 | 2015-03-24 | Baxter International Inc. | IgG stimulated remyelination of peripheral nerves |
| JP6379113B2 (ja) | 2013-02-26 | 2018-08-22 | バクスアルタ インコーポレイテッド | 免疫グロブリンｇの鼻腔内投与による中枢神経系障害の治療 |
| ES2740127T3 (es) | 2013-05-06 | 2020-02-05 | Baxalta Inc | Tratamiento de subpoblaciones con enfermedad de Alzheimer con inmunoglobulina G combinada |
| MX2024010855A (es) | 2022-03-07 | 2024-09-11 | Takeda Pharmaceuticals Co | Produccion cromatografica de afinidad de productos clinicos de inmunoglobulina g (igg) humana. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL286954A (cg-RX-API-DMAC7.html) * | 1962-01-03 | |||
| BE713764A (cg-RX-API-DMAC7.html) * | 1967-05-01 | 1968-09-16 | Baxter Travenol Lab | |
| AT275038B (de) * | 1967-11-15 | 1969-10-10 | Immuno Ag | Verfahren zur Gewinnung von reinem Blutalbumin aus Hämopigmente enthaltenden Proteinlösungen |
-
1970
- 1970-06-02 SE SE763270A patent/SE348942B/xx unknown
-
1971
- 1971-05-28 GB GB1784271A patent/GB1344340A/en not_active Expired
- 1971-06-01 CH CH793671A patent/CH572745A5/xx not_active IP Right Cessation
- 1971-06-01 DE DE19712127159 patent/DE2127159C2/de not_active Expired
- 1971-06-01 CA CA114,557A patent/CA960964A/en not_active Expired
- 1971-06-01 NL NL7107529A patent/NL177599C/xx not_active IP Right Cessation
- 1971-06-01 AT AT471971A patent/AT309678B/de active
- 1971-06-02 FR FR7119993A patent/FR2100716B1/fr not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2751717A1 (de) * | 1976-12-03 | 1978-07-13 | Myer Louis Dr Coval | Neue verbesserte gammaglobuline fuer intravenoese injektion und verfahren zu ihrer herstellung |
Also Published As
| Publication number | Publication date |
|---|---|
| NL177599C (nl) | 1985-10-16 |
| GB1344340A (en) | 1974-01-23 |
| SE348942B (cg-RX-API-DMAC7.html) | 1972-09-18 |
| FR2100716B1 (cg-RX-API-DMAC7.html) | 1975-06-06 |
| DE2127159A1 (de) | 1971-12-09 |
| NL177599B (nl) | 1985-05-17 |
| NL7107529A (cg-RX-API-DMAC7.html) | 1971-12-06 |
| FR2100716A1 (cg-RX-API-DMAC7.html) | 1972-03-24 |
| CH572745A5 (cg-RX-API-DMAC7.html) | 1976-02-27 |
| CA960964A (en) | 1975-01-14 |
| AT309678B (de) | 1973-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2127159C2 (de) | IgG-Immunglobulinfraktion und ihre Herstellung | |
| DE2645466C2 (de) | Verfahren zum Isolieren von Albumin aus Plasmaprodukten | |
| EP0013901B1 (de) | Verfahren zur Herstellung einer für die intravenöse Applikation geeigneten Immunglobulinlösung, die IgM in ankonzentrierter Form enthält | |
| DE2720704C2 (de) | Neues Glycoprotein, Verfahren zu seiner Herstellung und seine Verwendung | |
| DE60102144T2 (de) | EINE METHODE ZUR HERSTELLUNG VON IgG | |
| DE2801123C2 (de) | Verfahren zur Herstellung eines intravenös applizierbaren Serumeiweiß-Präparates | |
| EP0000134B1 (de) | Glykoprotein, Verfahren zu seiner Herstellung, seine Verwendung zur Gewinnung von Antiserum sowie das Antiserum | |
| DE3218348A1 (de) | Verfahren zur extraktion von proteinen, insbesondere von lactoferrin und immunglobulinen aus milch | |
| DE3927111A1 (de) | Nicht modifizierte intravenoes verabreichbare igm- und/oder iga-haltige immunglobulinpraeparate und verfahren zu ihrer herstellung | |
| EP0060491B1 (de) | Protein (PP16), Verfahren zu seiner Anreicherung und Gewinnung sowie seine Verwendung | |
| EP0033000A1 (de) | Neues Protein PP15, ein Verfahren zu seiner Herstellung sowie seine Verwendung | |
| DE68911693T2 (de) | Pharmazeutisches mittel für behandlung von menschlichem krebs und verfahren zu seiner herstellung. | |
| CH633809A5 (de) | Verfahren zur herstellung einer serumalbuminfraktion. | |
| DE10029705A1 (de) | Herstellung von IgY(AFc)-Antikörpern und deren Verwendung | |
| DE1617805C3 (de) | Verfahren zur Gewinnung von Lysozym aus Eiweiß | |
| DE2732998A1 (de) | Verfahren zur herstellung von serumalbumin | |
| DE69030414T2 (de) | Reinigung von Albumin | |
| CH632091A5 (en) | Process for the preparation of an antiserum directed against placenta-specific glycoprotein | |
| EP0035726B1 (de) | Verfahren und diagnostisches Mittel zur direkten Bestimmung des Lipidgehaltes der beta-Lipoproteine des Blutes | |
| DE1617332C3 (de) | Verfahren zum Isolieren eines wasserlöslichen Protein-Metall-Chelats mit antiphlogistischer Wirkung | |
| DE3410694C2 (cg-RX-API-DMAC7.html) | ||
| EP0029191A1 (de) | Neues Protein PP11, ein Verfahren zu seiner Gewinnung und seine Verwendung | |
| DE69632066T2 (de) | Verfahren zur reinigung der urease aus helicobacter pylori | |
| DE10065227A1 (de) | Verfahren zur Isolierung und Reinigung von Eigelb-Antikörpern aus Vogeleiweiß und Verwendung von dadurch erhaltenen Eigelb-Antikörpern | |
| DE3034529C2 (de) | Leukorekrutin: Ein Entzündungsmediatorprotein aus Säugerserum zur Induzierung einer Leukozytosereaktion, Herstellungsverfahren, Gewinnung in molekular einheitlicher, kristallisierbarer und biologisch spezifisch wirkender Form und Leukorekrutin enthaltendes Arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| D2 | Grant after examination |